{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:27:47Z","timestamp":1786429667048,"version":"build-2736575974"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hematologic neoplasms remain a growing global burden, with relapse, resistance, and limited treatment options persisting. Bispecific antibodies (BsAbs) offer a novel multi-antigen targeting strategy. This systematic review assesses their efficacy and safety, offering an in-depth appraisal of their therapeutic potential and the unmet medical needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted this systematic review following the PRISMA 2020 guidelines. Articles published up to 20 June 2026 were searched across PubMed, Scopus, Web of Science, and Embase. Efficacy outcomes such as measurable residual disease (MRD), overall response rate (ORR), complete response (CR), overall survival (OS), and progression-free survival (PFS), as well as safety outcomes such as severe adverse events (SAEs), grade \u22653 adverse events (\u22653 AEs), hematologic and non-hematologic toxicities were systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-six studies evaluating nineteen different BsAbs were included. Blinatumomab (CD3-CD19) remains the most extensively studied bispecific antibody in relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R\/R BCP-ALL). CD3-CD20 BsAbs (Glofitamab, Epcoritamab) demonstrated durability in non-Hodgkin lymphoma (NHL). In multiple myeloma (MM), BCMA- and GPRC5D-targeting BsAbs achieved MRD negativity and deep responses including very good partial response (VGPR) and stringent complete response (sCR). BsAbs in acute myeloid leukemia (AML) and Hodgkin\/T-cell lymphoma (HL\/TCL) remained early-phase with limited efficacy and no approvals to date. Cytokine release syndrome (CRS) and neurotoxicity were the dominant toxicities of CD3-engaging agents (neurologic events &amp;gt;50% in several Blinatumomab studies). Teclistamab (CD3\u2013BCMA) and Talquetamab (CD3\u2013GPRC5D) were associated with frequent CRS, with neurotoxicity also reported. However, hematologic toxicity and infections remain major challenges in multiple myeloma treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BsAbs demonstrate established clinical activity in BCP-ALL, B-cell NHL, and MM but remain under investigation in AML, HL, and T-cell lymphoma. CRS, neurotoxicity, cytopenias, and infections remain key safety considerations. Further studies should optimize treatment strategies and evaluate emerging targets and non-CD3-engaging bispecific antibodies.<\/jats:p>\n                    <jats:p>The protocol was prospectively registered in PROSPERO (CRD42023467556).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD42023467556.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1815519","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:10Z","timestamp":1786426510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Khanittha","family":"Lommuang","sequence":"first","affiliation":[{"name":"Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthira","family":"Taychakhoonavudh","sequence":"additional","affiliation":[{"name":"Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-75387-2_149","article-title":"Hematological neoplasms","volume-title":"Intraocular Inflammation","author":"Zierhut","year":"2016"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530150823","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3322\/canjclin.55.6.368","article-title":"Non-hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic Malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0228","article-title":"Battling the hematological Malignancies: The 200 years' war","volume":"13","author":"Lichtman","year":"2008","journal-title":"Oncologist"},{"key":"B8","article-title":"Estimated age-standardized incidence rates (World) in 2020, World, both sexes, all ages (excl. NMSC)","volume":"71","year":"2023"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14035","article-title":"Comparing end-of-life care of hematologic Malignancy versus solid tumor patients in a tertiary care center","volume":"111","author":"Burstein","year":"2023","journal-title":"Eur J Haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/ejh.13203","article-title":"Haematological Malignancy: Are we measuring what is important to patients? A systematic review of quality-of-life instruments","volume":"102","author":"Goswami","year":"2019","journal-title":"Eur J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.01.003","article-title":"Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance","volume":"14","author":"Shapira","year":"2011","journal-title":"Drug Resist Update"},{"key":"B12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic Malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduction Tgt Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.04.005","article-title":"Antigen loss after targeted immunotherapy in hematological Malignancies","volume":"41","author":"Zhou","year":"2021","journal-title":"Clin Lab Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: Target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000249","article-title":"Relapsed disease: off-the-shelf immunotherapies vs customized engineered products","volume":"2021","author":"Karmali","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: first approval","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2064981","article-title":"Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL","volume":"63","author":"Katz","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100110","article-title":"Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Hutchings","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-026-01796-5","article-title":"A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell Malignancies","volume":"19","author":"Wang","year":"2026","journal-title":"J Hematol Oncol"},{"key":"B35","unstructured":"FDA approves epcoritamab-bysp for follicular lymphoma indications: U.S. Food and Drug Administration (FDA)\n          \n          \n          \n          2025"},{"key":"B36","unstructured":"FDA approves Roche's Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma\n          \n          \n          Roche Media Release\n          \n          2025"},{"key":"B37","unstructured":"FDA grants accelerated approval to linvoseltamab\u00e2\u20ac\u2018gcpt for relapsed or refractory multiple myeloma\n          \n          \n          Silver Spring (MD)\n          U.S. Food and Drug Administration\n          \n          2025"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2603870","article-title":"Teclistamab in multiple myeloma with one to three previous lines of therapy","author":"Touzeau","year":"2026","journal-title":"N Engl J Med"},{"key":"B39","unstructured":"FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma: U.S. Food and Drug Administration (FDA)\n          \n          \n          \n          2026"},{"key":"B40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s44228-022-00023-5","article-title":"Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA\/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma","volume":"5","author":"Plesner","year":"2023","journal-title":"Clin Hematol Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01883-3","article-title":"Preclinical discovery and initial clinical data of WVT078, a BCMA x CD3 bispecific antibody","volume":"37","author":"Raab","year":"2023","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2528115","article-title":"BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study","volume":"66","author":"Rodriguez","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell Malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1158\/1078-0432.ccr-24-1913","article-title":"A phase II study of Acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute lymphoblastic leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0048","article-title":"NCCN guidelines\u00ae Insights: B-cell lymphomas 3.2025","volume":"23","author":"Zelenetz","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0001","article-title":"Multiple myeloma, version 5.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Kumar","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71562","article-title":"Bispecific antibodies versus chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma: a comparative narrative review of efficacy, safety, and accessibility","volume":"15","author":"Abou","year":"2026","journal-title":"Cancer Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2024.104265","article-title":"Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today","volume":"54","author":"Zhou","year":"2025","journal-title":"La Presse M\u00e9dicale"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_432204","article-title":"Charting the course: sequencing immunotherapy for multiple myeloma","volume":"44","author":"Mohan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2026.03.003","article-title":"The evolution of chimeric antigen receptor T-cell, bispecific antibodies and antibody\u2013drug conjugates for the treatment of multiple myeloma","volume":"26","author":"Cani","year":"2026","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17474086.2024.2353751","article-title":"Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed\/refractory multiple myeloma","volume":"17","author":"Moore","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.25055","article-title":"Development and biomarkers of CD20\/CD3 bispecific antibodies in diffuse large B-cell lymphoma","volume":"65","author":"Iriyama","year":"2025","journal-title":"J Clin Exp Hematop"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/medicina62061056","article-title":"CD20 \u00d7 CD3 bispecific antibodies in B-cell non-Hodgkin lymphomas: current evidence, therapeutic integration, and future directions","volume":"62","author":"Giamaiou","year":"2026","journal-title":"Medicina"},{"key":"B76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s40425-019-0606-0","article-title":"Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia","volume":"7","author":"Marklin","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/antib15010005","article-title":"Bispecific antibodies: strategies available to optimize their safe delivery in patients with multiple myeloma","volume":"15","author":"Giles","year":"2026","journal-title":"Antibodies (Basel)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40259-025-00735-z","article-title":"Bispecific antibodies in hematologic Malignancies: attacking the frontline","volume":"39","author":"Shastri","year":"2025","journal-title":"BioDrugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815519\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:12Z","timestamp":1786426512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815519\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2026.1815519"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1815519","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1815519"}}